Cardo Medical Announces Femur-First Versatility With Its Uni-Compartmental Knee System

Cardo Medical
(OTCBB: CDOM), a company engaged in the development of orthopedic
medical devices, announces the femur-first versatility in surgical
technique with its Uni-Compartmental Knee System. Uni-compartmental
knee arthroplasty procedures are most commonly performed using
tibial-first referencing surgical techniques; however the Cardo
Medical Uni-Compartmental Knee system also provides surgeons with
additional intra-operative versatility to easily adapt to femur-first
surgical techniques. Dr. Andrew Yun, an orthopedic surgeon at St.
John's Hospital in Santa Monica, CA, has performed numerous
femur-first uni-compartmental arthroplasty procedures and commented,
"I have been very satisfied with the ease of use and outcomes with
this system. The Cardo engineering team has been incredible to work
with, and I have enjoyed the responsiveness and quality of work which
comes from this group." In addition, Dr. Jonathan Braslow, an
orthopedic surgeon at JFK Memorial Hospital in Indio, CA, also
stated, "The Cardo Align 360 instrumentation system eliminates the
guesswork for the first cut, the system was easy and simple to use
and creates a reproducible outcome each time." The Align 360
Uni-Compartmental Knee System, Cardo Medical's initial product
release, has been used successfully since its introduction in January
2007. System enhancements for the femur-first approach include novel,
unique femoral tibial alignment ("knee jack") instruments with
dedicated alignment and resection guides.



Dr. Andrew Brooks, Chairman and Chief Executive Officer of Cardo
Medical, stated, "The Cardo Medical Uni-Compartmental Knee system was
our first commercially available arthroplasty system, and also set
the standards of simplicity, versatility and reproducibility we
design into all our system offerings. The Align 360
Uni-Compartmental Knee system enables surgeons the flexibility to
choose between both a tibial-first or femoral-first referencing and
resection surgical technique and approach. With its innovative
alignment and conservative resection instrumentation, the system
easily adapts to any surgeons' training and methodology, including
use with mechanical or computer assisted surgical navigation. We are
pleased to offer intra-operative versatility within all of our
systems and continue to offer modularity and interchangeability,
especially within our Align 360 knee platform. Our innovations
especially with regards to instrumentation, surgical approaches and
techniques enable surgeons to achieve excellent surgical outcomes."



About Cardo Medical, Inc.



Cardo Medical (OTCBB: CDOM) develops reconstructive orthopedic and
spinal surgery products through advanced engineering and focuses on
product development, marketing and distribution within the US market.
Cardo Medical's superior engineering talent closely collaborates with
leading surgeons around the country to create products that reduce or
eliminate joint pain and allow patients to achieve more active lives.
The company's cutting edge products are specifically developed with
patients, surgeons and OR staff in mind and are designed to reduce
operative time, enhance surgical technique, shorten hospital stays,
reduce recovery time and improve outcomes. Cardo Medical's product
portfolio includes devices for knee, hip, spinal fusion and motion
preservation arthroplasty and replacement, many of which have already
received FDA clearance. Cardo Medical has a robust and innovative
product pipeline pending both USPTO and FDA submission and clearance.
















Cardo Medical works in small, focused development teams in concert
with physicians to rapidly develop products from concept to launch. We
are committed to exceeding the standards by which any device company
is judged. Please visit our website at cardomedical for more
information on the Align 360 Uni-Compartmental Knee System in
addition to our portfolio of other Reconstructive and Spinal Implant
systems.



This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), regarding product development efforts and other
non-historical facts about expectations, beliefs or intentions
regarding the business, technologies and products, financial
condition, strategies or prospects. Many factors could cause actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements. These factors
include those described in our filings with the Securities and
Exchange Commission, as well as risks inherent in funding, developing
and obtaining regulatory approvals of new, commercially-viable and
competitive products and treatments, including the risks that any
products under development may fail, may not achieve the expected
results or effectiveness and may not generate data that would support
the approval or marketing of products for the ailments being studied
or for other ailments. In addition, forward-looking statements also
may be adversely affected by general market factors, competitive
product development, product availability, federal and state
regulations and legislation, the regulatory process for new products
and indications, manufacturing issues that may arise, patent
positions and litigation, among other factors. We do not undertake
any obligation to update forward-looking statements. We intend that
all forward-looking statements be subject to the safe-harbor
provisions of the PSLRA.

Cardo Medical